References
- Biovia, D. S. (2015). Discovery studio modeling environment. San Diego: Dassault Systèmes
- Bivona, T. G., & Doebele, R. C. (2016). A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nature Medicine, 22(5), 472.
- Cappuzzo, F., Jänne, P., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., & Roncalli, M. (2008). MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Annals of Oncology, 20(2), 298–304.
- Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., & Perry, J. K. (2004). Glide: a new approach for rapid, Accurate Docking and Scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749.
- Goddard, J.-P., & Reymond, J.-L. (2004). Enzyme assays for high-throughput screening. Current Opinion in Biotechnology, 15(4), 314–322.
- Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., & Horn, L. (2015). AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. New England Journal of Medicine, 372(18), 1689–1699.
- Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., & Halmos, B. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 352(8), 786–792.
- Li, Y., Guessous, F., Johnson, E. B., Eberhart, C. G., Li, X.-N., Shu, Q., & Schiff, D. (2008). Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Laboratory Investigation, 88(2), 98.
- Parenti, M. D., & Rastelli, G. (2012). Advances and applications of binding affinity prediction methods in drug discovery. Biotechnology advances, 30(1), 244–250.
- Release, S. (2014). 1: Desmond molecular dynamics system, version 3.7. DE Shaw research. New York, NY: Maestro-Desmond Interoperability Tools, Version, 3.
- Robinson, K. W., & Sandler, A. B. (2013). The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. The Oncologist, 18(2), 115–122.
- Singh, P. K., & Silakari, O. (2017a). chemotherapeutics-resistance “arms; race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer ”. Life sciences, 186, 25–32.
- Singh, P. K., & Silakari, O. (2017b). Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer. Future medicinal chemistry, 9(5), 469–483.
- Singh, P. K., Singh, H., & Silakari, O. (2016). Kinases inhibitors in lung cancer: From benchside to bedside. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1866(1), 128–140.
- Yano, S., Yamada, T., Takeuchi, S., Tachibana, K., Minami, Y., Yatabe, Y., Kudoh, S. (2011). Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. Journal of thoracic oncology, 6(12). 2011–2017